Trudhesa™ Nasal Spray for the Treatment of Migraines
Migraine relief medications are frequently monitored and flagged for audit due to high cost, quantities submitted, days’ supply and/or frequency of refills. Trudhesa™ 4 mg/mL nasal spray was FDA approved on September 3, 2021. It is indicated for the acute treatment of migraine with or without aura in adults. While Migranal® and Trudhesa™ are both nasal sprays containing dihydroergotamine, Trudhesa™ is the newer form made to reach the bloodstream more quickly by being absorbed better through the nose. Pharmacies often struggle on billing Trudhesa™, due to some specific dosing and administration guidelines. Please see below for guidance on how to properly bill for this migraine relief medication.
- Continuous Glucose Monitors and Potential Audit Risk with PHE Ending - May 26, 2023
- Avoiding Humana Audits for Deceased Patients - May 9, 2023
- A Documentation Checklist for Continuous Glucose Monitor Claims - April 15, 2023